ACM
ADMA icon

Accent Capital Management’s ADMA Biologics ADMA Stock Holding History

Accent Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.87K Buy
+701
New +$6.39K ﹤0.01% 275

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Accent Capital Management's ADMA Position: Q2 2026 in Review

Accent Capital Management opened a new position in ADMA Biologics (ADMA) in Q2 2026: 701 shares worth $5.87K. The stake represents ﹤0.01% of the portfolio and ranks #275 among its holdings.

323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Accent Capital Management held 701 shares of ADMA Biologics worth $5.87K as of Q2 2026.
  • ADMA Biologics was a new Accent Capital Management position in Q2 2026.
  • ADMA Biologics made up ﹤0.01% of Accent Capital Management's portfolio in Q2 2026, its #275 holding.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Accent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.